GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Pretax Margin %

AVANIR Pharmaceuticals (FRA:AV2B) Pretax Margin % : -43.14% (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. AVANIR Pharmaceuticals's Pre-Tax Income for the three months ended in Sep. 2014 was €-10.95 Mil. AVANIR Pharmaceuticals's Revenue for the three months ended in Sep. 2014 was €25.38 Mil. Therefore, AVANIR Pharmaceuticals's pretax margin for the quarter that ended in Sep. 2014 was -43.14%.

The historical rank and industry rank for AVANIR Pharmaceuticals's Pretax Margin % or its related term are showing as below:

FRA:AV2B' s Pretax Margin % Range Over the Past 10 Years
Min: -952.56   Med: -319.21   Max: -43.84
Current: -43.84


FRA:AV2B's Pretax Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 4.33 vs FRA:AV2B: -43.84

AVANIR Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for AVANIR Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Pretax Margin % Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -921.91 -577.60 -144.74 -100.14 -43.84

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -163.71 -40.93 -47.05 -44.35 -43.14

Competitive Comparison of AVANIR Pharmaceuticals's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Pretax Margin % falls into.



AVANIR Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

AVANIR Pharmaceuticals's Pretax Margin for the fiscal year that ended in Sep. 2014 is calculated as

Pretax Margin=Pre-Tax Income (A: Sep. 2014 )/Revenue (A: Sep. 2014 )
=-39.136/89.263
=-43.84 %

AVANIR Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2014 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2014 )/Revenue (Q: Sep. 2014 )
=-10.949/25.379
=-43.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVANIR Pharmaceuticals  (FRA:AV2B) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


AVANIR Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines